Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to Agrawal and Kumar.
Kansagra K, Parmar D, Mendiratta SK, Patel J, Joshi S, Sharma N, Parihar A, Bhoge S, Patel H, Kalita P, Munshi R, Kurmi P, Shah R, Gupta A, Bhalla HL, Bekkalele H, Verma RK, Agarwal D, Sharma S, Gawande A, Chhaya G. Kansagra K, et al. Among authors: mendiratta sk. Clin Infect Dis. 2021 Aug 2;73(3):e846. doi: 10.1093/cid/ciaa1507. Clin Infect Dis. 2021. PMID: 33011769 No abstract available.
A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG).
Kansagra K, Parmar D, Mendiratta SK, Patel J, Joshi S, Sharma N, Parihar A, Bhoge S, Patel H, Kalita P, Munshi R, Kurmi P, Shah R, Gupta A, Bhalla H, Bekkalele H, Verma R, Agarwal D, Sharma S, Gawande A, Chhaya G. Kansagra K, et al. Among authors: mendiratta sk. Clin Infect Dis. 2021 Nov 2;73(9):e2722-e2728. doi: 10.1093/cid/ciaa779. Clin Infect Dis. 2021. PMID: 32556113 Clinical Trial.
Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.
Bhushan B L S, Wanve S, Koradia P, Bhomia V, Soni P, Chakraborty S, Khobragade A, Joshi S, Mendiratta SK, Kansagra KK, Parihar A, Sharma S, Patel J; Study Investigators Group. Bhushan B L S, et al. Among authors: mendiratta sk. Int J Infect Dis. 2021 Oct;111:281-287. doi: 10.1016/j.ijid.2021.08.044. Epub 2021 Aug 21. Int J Infect Dis. 2021. PMID: 34428542 Free PMC article. Clinical Trial.
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G, Haridas V, Jain D, Mendiratta SK. Jani RH, et al. Among authors: mendiratta sk. Int J Rheum Dis. 2016 Nov;19(11):1157-1168. doi: 10.1111/1756-185X.12711. Epub 2015 Jul 14. Int J Rheum Dis. 2016. PMID: 26176644 Free PMC article. Clinical Trial.
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A, Bhatt N, Prakash SS, Biswas G, Nagarkar R, Roy B, Samal P, Agrawal N, Meshram S, Kaushal A, Satheesh CT, Wategaonkar R, Thiagarajan KV, Jain K, Vijayaveeran P, Mukherjee K, Singh K, Patil T, Jain A, Dolai TK, Jain M, Hingmire S, Gupta TC, Lakshmaiah KC, Rajamanickam D, Nemade B, Goyal V, Mahato P, Mendiratta SK, Doshi M. Patel A, et al. Among authors: mendiratta sk. Cancer Chemother Pharmacol. 2023 Jun;91(6):457-468. doi: 10.1007/s00280-023-04530-x. Epub 2023 Apr 24. Cancer Chemother Pharmacol. 2023. PMID: 37093266 Free PMC article. Clinical Trial.
63 results